Event Details
The prolonged nature of the pandemic has strained many healthcare systems around the world, including Singapore. However, Singapore's foresight to strategically position the country as a health innovation and medical hub has contributed to its healthcare system's unwavering dependability even as new strains continues to emerge. Nonetheless, the long-term health needs of Singaporeans and economic survival continue to be top of mind.
Singapore is ramping up efforts to continue to build up its biopharma, R&D, science and technology ecosystem through its commitments under the Research, Innovation and Enterprise (or RIE) 2025 plan. The country ranks as the world's 8th most-innovative economy in the world, and top in Asia for the past seven years by the Global Innovation Index. Home to a growing and diverse R&D pool as well as an advanced drug development hub, Singapore is poised to lead the charge in becoming a global mode for advanced therapeutics and medicines innovation such as cell and gene therapy. There are now at least 3,000 biotech start-ups that are based in Singapore.
The last two years also saw platforms such as CRIS and other public-private consortiums to accelerate end-to-end innovation. With this strong foundation, where and how can the health and life sciences further develop in the next 30 years to build a pandemic-resilient Singapore? As we look ahead beyond Singapore Budget 2022, what can we expect as we look to build back better our health system and economy?
Hear from key experts on their thoughts on how Singapore can better transform and protect health, advance human potential, and create economic value for Singapore in 2022 and beyond.
* For any enquires please contact the AmCham Programming and Events Team at pe@amcham.com.sg.
